Multiple sclerosis (MS) is a common autoimmune disease of the central nervous system, causing neurological disability in young adults. A growing understanding of its immunopathogenesis has led to an expanding array of therapies. Notable new advances in disease-modifying therapies for relapsing forms of multiple sclerosis that are based on anti-inflammatory activity have recently been developed. Management of progressive MS is still challenging. Data published in 2014 suggested that daily high doses of biotin, a vitamin involved in myelin synthesis, might have a beneficial impact on disability and progression in progressive MS. However, some patients worsened while on biotin without any clear explanation for this effect. We report the case of a 41-year-old patient suffering from primary progressive (PP) MS who presented after 16 months of treatment with high doses of biotin (QIZENDAY) with worsening of his Expanding Disability Status Scale (EDSS) score and the appearance of a symptomatic new T2 pseudo-tumoural lesion on brain magnetic resonance imaging (MRI), suggestive of tardive inflammatory reactivation possibly due to the biotin. The newer and more effective therapies for MS are, however, associated with risks that necessitate an active management strategy and continuous vigilance. Physicians should be aware of iatrogenic neurological complications and the possible paradoxical effects of biotin. Future treatment approaches to progressive MS must include identification of a biomarker of disease activity. The study of neurofilaments in the cerebrospinal fluid (CSF) and the serum could be of interest when determining the optimal treatment strategy.
The forthcoming Enhanced Games, scheduled for May 2026 in Las Vegas, mark a disruptive moment in the history of competitive sports. By institutionalising the use of performance-enhancing drugs under the guise of autonomy and medical supervision, these games promote a vision of human excellence rooted in pharmacological enhancement rather than natural talent and training. This article examines the medical, ethical and societal implications of such a paradigm shift. Drawing parallels with the Roman strategy of panem et circenses, we argue that the Enhanced Games represent not just a spectacle but a profound redefinition of athletic values, where health risks are commodified, ethical norms are undermined, and youth are exposed to dangerous models of success. Despite claims of harm reduction and innovation, the systemic normalisation of doping threatens to erode the spirit of sport and burden public health systems with iatrogenic consequences. We call for an urgent multidisciplinary dialogue involving physicians, ethicists, neuroscientists and policymakers to assess this trend and safeguard the principles of equity, integrity and well-being in competitive performance.
In the psychological thriller film Joker, released in 2019 and starring Joaquin Phoenix in the first role, another possible origin story for this iconic character is reported. Above all, it brings us medical elements for the understanding of the development of this complex character. Contrary to other interpretations, we discover a lonely, timid and uncharismatic man (Arthur Fleck). He seems to be suffering from psychobehavioral disorders and seems depressed. There is a strangeness in his behavior along with social withdrawal. He suffers from fits of laughter that occur at socially inappropriate times. He also suffers from psychotic symptoms with visual delusions. We learn through the film that he was a beaten child, psychologically and physically abused with severe traumatic brain injury (TBI). The uncontrollable outbursts of laughter, behavioral and psychotic disorders followed these elements. As a neurologist, I was intrigued by these symptoms. I have explored the neuropsychiatric symptoms complicating TBI from which he seems to suffer and which have been reported in the literature. We can assume that the Joker is suffering from neuropsychiatric sequelae related to childhood TBI involving the frontotemporal regions and, in particular, the lateral aspect of the left frontal lobe. The movie Joker has medical significance and covers social aspects of medicine and health care. First, it allows us to discuss whether psychotic disorder due to TBI should be considered a neurobiological syndrome. More broadly, albeit fictitious, it asks us about the management of patients with neuropsychiatric illness, which is a public health problem. It also reminds us that semiological descriptions of patients with neuropsychiatric disorders have served as inspiration for many authors.
Background: Alice in Wonderland Syndrome (AIWS) is characterized by transient distortions in visual perception—alterations in size, shape, and spatial relationships—typically described in migraine or encephalitis. Its occurrence in neurodegenerative conditions, particularly in dementia with Lewy bodies (DLB), remains exceedingly rare.Case description: This article reports a case of a 68-year-old patient with dementia with Lewy bodies (DLB; limbic-early subtype) who presented with typical DLB features alongside a brief episode of misperception—reporting that his bed had “shrunk.” Neuroimaging revealed diffuse cortical atrophy with prominent bi-hippocampal and parietal lobe involvement, and hypoperfusion on HMPAO SPECT.Conclusion: This is the first reported case of AIWS in a patient with DLB. We hypothesize that selective dysfunction of high-level visual networks—particularly in the right extrastriate cortex responsible for the canonical storage of object size—may lead to an agnosia of object size. This case underscores the importance of considering AIWS within the spectrum of visual disturbances in DLB.Theoretical implications: These findings provide novel insights into the neurobiology of visual cognition, aligning with Husserl’s concept of the “primordial body” (Urleib) and intuition. They suggest that disruptions in the integration of visual sensory inputs and canonical object properties may critically influence the conscious reconstruction of reality.
Melioidosis is an endemic disease in South-East Asia and Northern Australia caused by a Gram-negative bacillus, Burkholderia pseudomallei. Manifestations are wide and neurological involvement have rarely been described. In this paper, we report a patient returning from Asia with an unusual infection including CNS involvement consistent with a melioidosis. This diagnosis was challenging and complex to carry out with multiple considerations, mainly because of the atypical nature of the germ. Burkholderia pseudomallei can be easily misidentified with Burkholderia thailandensis (rarely pathogenic to humans) during bacterial culture because of their phylogenetic proximity. The main pitfall of the management was that the responsible infectious agent was not referenced in the MALDI-TOF (considered as a bioterrorism agent) and led to a wrong strategy. This case of melioidosis shows the difficulty regarding the diagnosis of this disease in a patient returning from an endemic zone and its frequent multiple organs involvement. Melioidosis is an emerging, potentially fatal disease which requires prolonged antibiotic treatment. Difficulties in clinical microbiology laboratories diagnosis of melioidosis, especially in non-endemic areas where clinical suspicion is low, may delay treatment and affect disease outcomes.